Citius Pharmaceuticals
CTXR
7 hedge funds and large institutions have $1.21M invested in Citius Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
17% more funds holding
Funds holding: 6 → 7 (+1)
0.08% less ownership
Funds ownership: 0.28% → 0.2% (-0.08%)
44% less capital invested
Capital invested by funds: $2.17M → $1.21M (-$959K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Miller Investment Management
West Conshohocken,
Pennsylvania
|
+$106K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$61.3K |
| 3 |
Morgan Stanley
New York
|
+$66 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$622K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$7.91K |
| 3 |
HFM
Hartford Financial Management
Hartford,
Connecticut
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $937K | -$622K | -9,361 | -36% |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $113K | +$61.3K | +923 | +89% |
|
|
MIM
3
Miller Investment Management
West Conshohocken,
Pennsylvania
| $92K | +$106K | +1,600 | New |
|
4
Dimensional Fund Advisors
Austin,
Texas
| $32K | – | – | – |
|
|
RJA
5
Raymond James & Associates
St Petersburg,
Florida
| $28K | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $6K | -$7.91K | -119 | -54% |
|
|
HFM
7
Hartford Financial Management
Hartford,
Connecticut
| – | -$1K | -20 | Closed |
|
|
8
Morgan Stanley
New York
| – | +$66 | +1 | New |
|
CTXR Hedge Fund Activity: Q2 2018 in Review
7 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q2 2018, worth a combined $1.21M — down 44% from $2.17M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new CTXR positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Miller Investment Management, opening a new position worth an estimated $106K. The largest seller was Sabby Management, cutting an estimated $622K.
- 7 institutional investors held Citius Pharmaceuticals (CTXR) as of Q2 2018, up from 6 in Q1 2018.
- Funds reported $1.21M of Citius Pharmaceuticals stock for Q2 2018, down 44% quarter-over-quarter.
- 2 funds opened new Citius Pharmaceuticals positions in Q2 2018 and 1 closed out, a net change of +1 holder.
- The largest Citius Pharmaceuticals buyer in Q2 2018 was Miller Investment Management, an estimated $106K added.
- The largest Citius Pharmaceuticals seller in Q2 2018 was Sabby Management, an estimated $622K sold.
Based on aggregated 13F filings for Q2 2018.